Dendreon is a biotechnology firm focused on the discovery, development, and commercialization of novel cancer therapies. The company's only marketed product is prostate cancer treatment Provenge, the first active cellular immunotherapy for cancer to hit the market. Dendreon also has other oncology immunotherapies and small-molecule drug candidates in preclinical and early clinical development. |